No abstract

Three new palladium complexes ([Pd(DABA)Cl2], [Pd(CPDA)Cl2], and [Pd(HZPY)Cl2]) bearing dinitrogen ligands (DABA: 3,4-diaminobenzoic acid; CPDA: 4-chloro–o-phenylenediamine; HZPY: 2-hydraziniopyridine) were synthesized, characterized, and tested against breast cancer (MCF-7), prostate carcinoma cell line (PC3) and liver carcinoma cell line (HEPG2). [Pd(DABA)Cl2] complex exhibited the highest inhibition percentage, lying between 68–71%. The hydrolysis mechanism of each palladium complex, the key step preceding the binding to the biological target, as well as their photophysical properties were explored by means of DFT and TDDFT computations. Results indicate a faster hydrolysis process for the Pd(DABA)Cl2 complex. The computed activation energies for the first and second hydrolysis processes suggest that all the compounds could reach DNA in their monohydrated form.

No abstract

New water soluble Ru(II) binary complex [Ru(C 5 H 7 N 3 )(X)(H 2 O) 2 ] with 2-hydrazinopyridine and its ternary complexes with X = dichloride, oxalate, malonate or pyrophosphate ligands have been synthesized. The complexes have been characterized using elemental analyses, mass, IR, and UV-Vis. spectroscopies, cyclic voltammetry, magnetic susceptibility, and thermal analysis. The complexes are diamagnetic and the electronic spectral data showed that peaks are due to low spin octahedral Ru(II) complexes. The optimized structures of the complexes 1-4 indicate distorted octahedral geometry with bond angles around the ruthenium atom ranged from 80.44° to 99.64°. The values of the electronic energies (-635 to -1145 a.u.), the highest occupied molecular orbital energies (-0.181 to 0.073 a.u.) and lowest unoccupied molecular orbital energies (-0.056 to 0.167 a.u.) indicate the stability of the complexes. The complexes are polarized as indicated from the dipole moment values (9.39-14.27 Debye). The complexes have noticeable cytotoxicity with IC 50 (μM): 0.